

9 December 2020

Mr. Hassan Abdulrahman Al Serkal
Chief Executive Officer
Dubai Financial Market
Dubai, UAE

Commenting on published news

Reference to the above mentioned subject; and in accordance with Chapter 10 of the Capital Markets Authority's bylaws of Law No. 7 of the year 2010 on Disclosure and Transparency as well as its subsequent amendments and resolutions, Agility would like to announce:

Date	9 December 2020
Company Name	Agility Public Warehousing Company KSCP
Material Information	Reference to what was published in the news under "Avigan® Approved for COVID-19 Treatment in Malaysia", Agility would like to announce that the Malaysian Ministry of Health's Drug Control Authority has approved Avigan® for use in treatment of COVID-19 patients. Earlier this year, Global Response Aid (GRA), an affiliate of Agility, and Dr. Reddy's Laboratories signed an agreement for exclusive global production, distribution and commercialization of the drug with its developer, FujiFilm Toyama Chemical.
Financial impact	Agility cannot assess the financial impact at the moment.

Best Regards,



Investor Relations Department

